Citation Impact
Citing Papers
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
2008 Standout
Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1)
2008
Pathophysiology of Migraine: A Disorder of Sensory Processing
2017 Standout
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
Tadalafil Therapy for Pulmonary Arterial Hypertension
2009 Standout
Selexipag for the Treatment of Pulmonary Arterial Hypertension
2015
PDF Cells Are a GABA-Responsive Wake-Promoting Component of the Drosophila Sleep Circuit
2008 StandoutNobel
Drug Interactions of Clinical Significance with Selective Serotonin Reuptake Inhibitors
1997
The Hypothalamic Orexinergic System: Pain and Primary Headaches
2007
Pathogenesis of Hepatorenal Syndrome: Implications for Therapy
2015
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Pediatric Pulmonary Hypertension
2013
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
2002
Formyl-Peptide Receptors in Infection, Inflammation, and Cancer
2018
Optogenetic deconstruction of sleep-wake circuitry in the brain
2010
Future Coastal Population Growth and Exposure to Sea-Level Rise and Coastal Flooding - A Global Assessment
2015 Standout
Updated Clinical Classification of Pulmonary Hypertension
2009 Standout
Drug-Induced Hepatotoxicity
2003 Standout
Emergency Hospitalizations for Adverse Drug Events in Older Americans
2011 Standout
Systemic sclerosis
2017 Standout
Aging Biology and Geriatric Clinical Pharmacology
2004
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers
2009
Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
2014
A micro cell culture analog (µCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs
2009
Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan
2006
Sleep Deprivation Effects on Circadian Clock Gene Expression in the Cerebral Cortex Parallel Electroencephalographic Differences among Mouse Strains
2008 StandoutNobel
Acute kidney injury
2019 Standout
Macrophages in Tissue Repair, Regeneration, and Fibrosis
2016 Standout
The Serotonin Syndrome
2005 Standout
Increased monoamine oxidase b activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography
1994
Microfluidic organs-on-chips
2014 Standout
Integration ofin silicoandin vitroplatforms for pharmacokinetic–pharmacodynamic modeling
2010
Remodelling the extracellular matrix in development and disease
2014 Standout
The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness
2007
Tolcapone and Hepatotoxic Effects
2000
Updated Clinical Classification of Pulmonary Hypertension
2013 Standout
Tadalafil: A Long-Acting Phosphodiesterase-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension
2011
Effects of Iron Supplementation and Depletion on Hypoxic Pulmonary Hypertension
2009 StandoutNobel
Hepatorenal Disorders
2015
Bosentan therapy for portopulmonary hypertension
2005
Orexin receptors as therapeutic drug targets
2012
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
2012 Standout
Pulmonary–Hepatic vascular Disorders (PHD)
2004
Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology
2022 Standout
The Implications of Multiple Circadian Clock Origins
2009 StandoutNobel
Portopulmonary Hypertension
2014
Genetics and Genomics of Pulmonary Arterial Hypertension
2013
Enantioselective synthesis of almorexant via iridium-catalysed intramolecular allylic amidation
2013 StandoutNobel
Orexin Receptor Antagonists: A New Concept In CNS Disorders?
2010
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
2015 Standout
Midazolam and Other Benzodiazepines
2008
Effects of entacapone and tolcapone on mitochondrial membrane potential
2002
Mammalian circadian signaling networks and therapeutic targets
2007
What’s new in the treatment of portopulmonary hypertension?
2015
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Raising the ‘Good’ Oxidants for Immune Protection
2021
The increase in pulmonary arterial pressure caused by hypoxia depends on iron status
2008 StandoutNobel
Genome-Wide Association Studies of Sleep Disorders
2011
Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension
2011
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency
2006
Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
2010
Mast cell and eosinophil surface receptors as targets for anti-allergic therapy
2016
Bosentan for the Treatment of Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension
2004
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
2017 Standout
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis
2014
Cu and Cu-Based Nanoparticles: Synthesis and Applications in Catalysis
2016 Standout
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Clinical iron deficiency disturbs normal human responses to hypoxia
2016 StandoutNobel
Diversity‐Oriented Syntheses by Combining CuAAC and Stereoselective INCIC Reactions with Peptides
2017 StandoutNobel
Recent advances in the synthesis of pyrroles by multicomponent reactions
2014 Standout
Pulmonary Arterial Hypertension
2006
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Control of Sleep and Wakefulness
2012
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
2019 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
ProTox-II: a webserver for the prediction of toxicity of chemicals
2018 Standout
Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine.
1995
Spermidine in health and disease
2018 StandoutScience
Biomedical Application of Orexin/Hypocretin Receptor Ligands in Neuroscience
2009
Chronic Thromboembolic Pulmonary Hypertension
2006 Standout
Hemodynamic and Clinical Correlates of Endothelin-1 in Chronic Thromboembolic Pulmonary Hypertension
2006
About Sleep's Role in Memory
2013 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage
2012 Standout
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
2009 Standout
Role of A2a Extracellular Adenosine Receptor-Mediated Signaling in Adenosine-Mediated Inhibition of T-Cell Activation and Expansion
1997 StandoutNobel
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Inflammation and metabolism in tissue repair and regeneration
2017 StandoutScience
Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension
2010
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
2018 Standout
Metal-Free Multicomponent Syntheses of Pyridines
2014 Standout
Effectiveness of Phosphodiesterase‐5 Inhibitor Therapy for Portopulmonary Hypertension
2015
Works of Jasper Dingemanse being referenced
Acute Hemodynamic Effects of Single‐Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS‐1 Study
2009
Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
2011
Integrated??Pharmacokinetics??and Pharmacodynamics in??Drug??Development
2007
Disposition and Metabolism of Setipiprant, a Selective Oral CRTH2 Antagonist, in Humans
2013
Promotion of sleep by targeting the orexin system in rats, dogs and humans
2007
Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects
2008
Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist
2004
Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant
2010
Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: An overview
1988
Pharmacokinetic-pharmacodynamic modelling of the EEG effects of Ro 48-6791, a new short-acting benzodiazepine, in young and elderly subjects
1997
Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects
2014
Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327
1991
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil
2007
Integrated pharmacokinetics and pharmacodynamics of Ro 48–6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects
1997
Influence of Mild Liver Impairment on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor Antagonist
2003
Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension
2012
Investigation of the Mutual Pharmacokinetic Interactions Between Bosentan, a Dual Endothelin Receptor Antagonist, and Simvastatin
2003
An update of recent moclobemide interaction data
1993
The effect of age on the pharmacokinetics and pharmacodynamics of midazolam
1999
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE‐1 study
2009
Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans
2012
A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist
2014
Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the “serotonin syndrome”*
1998
Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome
2007
Multiple-dose clinical pharmacology of the catechol- O -methyl-transferase inhibitor tolcapone in elderly subjects
1996
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
2015
Macitentan: entry-into-humans study with a new endothelin receptor antagonist
2011
The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure
2004
Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators
2016
Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease
1997
PP192—Pharmacokinetics of Selexipag in Subjects with Severe Renal Impairment Compared with Healthy Subjects
2013
A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects
2015
Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa.
1995
Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment
2013
Reply to 'Promotion of sleep by targeting the orexin system in rats, dogs and humans'
2007
Effects of the Endothelin Receptor Antagonist Bosentan on Hemodynamics, Symptoms and Functional Capacity in Japanese Patients With Severe Pulmonary Hypertension
2005
Moclobemide and fluvoxamine co‐administration: A prospective study in healty volunteers to investigate the potential development of the ‘serotonin syndrome’
1995
Biomarker‐guided clinical development of the first‐in‐class anti‐inflammatory FPR2/ALX agonist ACT‐389949
2016
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide
2002
Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study
2015
Setipiprant, a selective CRTH 2 antagonist, reduces allergen‐induced airway responses in allergic asthmatics
2014